BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 1996591)

  • 1. Local reactions to radioiodine in the treatment of thyroid cancer.
    Burmeister LA; du Cret RP; Mariash CN
    Am J Med; 1991 Feb; 90(2):217-22. PubMed ID: 1996591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioiodine lobar ablation as an alternative to completion thyroidectomy in patients with differentiated thyroid cancer.
    Bal CS; Kumar A; Pant GS
    Nucl Med Commun; 2003 Feb; 24(2):203-8. PubMed ID: 12548045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radioiodine dose for remnant ablation in differentiated thyroid carcinoma: a randomized clinical trial in 509 patients.
    Bal CS; Kumar A; Pant GS
    J Clin Endocrinol Metab; 2004 Apr; 89(4):1666-73. PubMed ID: 15070929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma.
    Tsang RW; Brierley JD; Simpson WJ; Panzarella T; Gospodarowicz MK; Sutcliffe SB
    Cancer; 1998 Jan; 82(2):375-88. PubMed ID: 9445196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategies of radioiodine ablation in patients with low-risk thyroid cancer.
    Schlumberger M; Catargi B; Borget I; Deandreis D; Zerdoud S; Bridji B; Bardet S; Leenhardt L; Bastie D; Schvartz C; Vera P; Morel O; Benisvy D; Bournaud C; Bonichon F; Dejax C; Toubert ME; Leboulleux S; Ricard M; Benhamou E;
    N Engl J Med; 2012 May; 366(18):1663-73. PubMed ID: 22551127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of low-dose iodine-131 ablation of post-operative thyroid remnants: a study of 69 cases.
    Leung SF; Law MW; Ho SK
    Br J Radiol; 1992 Oct; 65(778):905-9. PubMed ID: 1422665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Optimization of 131I ablation in patients with differentiated thyroid carcinoma: comparison of early outcomes of treatment with 100 mCi versus 60 mCi].
    Kukulska A; Krajewska J; Roskosz J; Handkiewicz-Junak D; Jarzab M; Paliczka E; Puch Z; Wygoda Z; Gubała E; Jarzab B
    Endokrynol Pol; 2006; 57(4):374-9. PubMed ID: 17006839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radioiodine ablation of residual tissue in thyroid cancer: relationship between administered activity, neck uptake and outcome.
    Logue JP; Tsang RW; Brierley JD; Simpson WJ
    Br J Radiol; 1994 Nov; 67(803):1127-31. PubMed ID: 7820407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: implications for radioiodine treatment.
    Bonnet S; Hartl D; Leboulleux S; Baudin E; Lumbroso JD; Al Ghuzlan A; Chami L; Schlumberger M; Travagli JP
    J Clin Endocrinol Metab; 2009 Apr; 94(4):1162-7. PubMed ID: 19116234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Overtherapy or undertherapy for papillary thyroid microcarcinoma? Therapeutic considerations for radioiodine ablation].
    Dietlein M; Schober O; Schicha H
    Nuklearmedizin; 2004 Aug; 43(4):107-14. PubMed ID: 15316576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of total thyroidectomy with therapeutic central and lateral neck dissection with a single dose of radioiodine in the treatment of regionally advanced papillary thyroid cancer and effects on serum thyroglobulin.
    Hughes DT; Miller BS; Cohen MS; Doherty GM; Gauger PG
    Ann Surg Oncol; 2014 May; 21(5):1647-52. PubMed ID: 24385210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Early evaluation of treatment effectiveness using 131I iodine radiotherapy in patients with differentiated thyroid cancer].
    Gawkowska-Suwińska M; Turska M; Roskosz J; Puch Z; Jurecka-Tuleja B; Handkiewicz-Junak D; Wygoda Z; Jarzab B
    Wiad Lek; 2001; 54 Suppl 1():278-88. PubMed ID: 12182036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radioiodine therapy for papillary and follicular thyroid carcinoma.
    Klain M; Ricard M; Leboulleux S; Baudin E; Schlumberger M
    Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S479-85. PubMed ID: 12192549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thyroid remnant ablation in patients with papillary cancer: a comparison of low, moderate, and high activities of radioiodine.
    Kusacic Kuna S; Samardzic T; Tesic V; Medvedec M; Kuna K; Bracic I; Despot M; Dodig D
    Nucl Med Commun; 2009 Apr; 30(4):263-9. PubMed ID: 19247212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of the efficacy of iodine-131 for thyroid ablation.
    Comtois R; Thériault C; Del Vecchio P
    J Nucl Med; 1993 Nov; 34(11):1927-30. PubMed ID: 8229236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differentiated thyroid cancer: radioiodine following lobectomy - a clinical feasibility study.
    Hoyes KP; Owens SE; Millns MM; Allan E
    Nucl Med Commun; 2004 Mar; 25(3):245-51. PubMed ID: 15094442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Commentary: Application of post-surgical stimulated thyroglobulin for radioiodine remnant ablation selection in low-risk papillary thyroid carcinoma.
    Terris DJ
    Head Neck; 2010 Jun; 32(6):698-9. PubMed ID: 20187017
    [No Abstract]   [Full Text] [Related]  

  • 18. Evaluation of low-dose radioiodine ablation therapy in postsurgical thyroid cancer patients.
    Ramanna L; Waxman AD; Brachman MB; Tanasescu DE; Sensel N; Braunstein GD
    Clin Nucl Med; 1985 Nov; 10(11):791-5. PubMed ID: 4075672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer.
    Mallick U; Harmer C; Yap B; Wadsley J; Clarke S; Moss L; Nicol A; Clark PM; Farnell K; McCready R; Smellie J; Franklyn JA; John R; Nutting CM; Newbold K; Lemon C; Gerrard G; Abdel-Hamid A; Hardman J; Macias E; Roques T; Whitaker S; Vijayan R; Alvarez P; Beare S; Forsyth S; Kadalayil L; Hackshaw A
    N Engl J Med; 2012 May; 366(18):1674-85. PubMed ID: 22551128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal.
    Pacini F; Molinaro E; Castagna MG; Lippi F; Ceccarelli C; Agate L; Elisei R; Pinchera A
    J Clin Endocrinol Metab; 2002 Sep; 87(9):4063-8. PubMed ID: 12213846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.